文献速递眼底病与葡萄膜炎

布西珠单抗治疗糖尿病性黄斑水肿的疗效与安全性:KINGFISHER随机临床试验

Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2023-01-01

这项52周双盲3期随机临床试验纳入517例糖尿病性黄斑水肿患者,按2:1随机接受布西珠单抗6mg或阿柏西普2mg每4周玻璃体腔注射。布西珠单抗在最佳矫正视力变化上非劣于阿柏西普,在无视网膜下液和视网膜内液的比例及中央亚区厚度改善上优于阿柏西普,未发现新的安全性问题。

要点

  • 第52周最佳矫正视力字母评分变化布西珠单抗12.2个字母 vs 阿柏西普11.0个字母,非劣效成立。
  • 无视网膜下液和视网膜内液比例布西珠单抗41.6% vs 阿柏西普22.2%,差异20.0%。
  • 中央亚区厚度变化布西珠单抗-237.8μm vs 阿柏西普-196.5μm,差异-41.4μm。

核心结论

  • 在糖尿病性黄斑水肿受试者中,布西珠单抗与阿柏西普两组视觉结局未见有临床意义的差异,布西珠单抗组部分解剖学改善更优,未发现新的安全性问题。

研究设计与样本

  • 52周双盲3期随机临床试验,纳入初治及既往接受过抗VEGF治疗的成人糖尿病性黄斑水肿患者,数据收集于2019年9月至2020年3月,数据分析于2020年4月至2021年2月。
  • 共517例受试者按2:1随机分配至布西珠单抗6mg组(n=346)或阿柏西普2mg组(n=171),每4周玻璃体腔注射一次。
  • 299例(57.8%)为男性,平均(标准差)年龄60.7(10.2)岁。

主要发现

  • 第52周最佳矫正视力(早期治疗糖尿病视网膜病变研究字母评分)较基线变化:布西珠单抗组改善12.2个字母,阿柏西普组改善11.0个字母,差异1.1(95%CI -0.6至2.9),非劣效界值4,P<.001。
  • 第52周无视网膜下液和视网膜内液的眼比例:布西珠单抗组346眼中144眼(41.6%),阿柏西普组171眼中38眼(22.2%),差异20.0%(95%CI 12.5至28.6),P<.001。
  • 第52周中央亚区厚度较基线平均变化:布西珠单抗组-237.8μm,阿柏西普组-196.5μm,差异-41.4(95%CI -58.9至-23.8),P<.001。
  • 眼内炎发生率布西珠单抗组4.0%(346眼中14眼),阿柏西普组2.9%(171眼中5眼);视网膜血管炎发生率分别为0.9%(346眼中3眼)和0.6%(171眼中1眼);视网膜血管阻塞发生率分别为0.3%(346眼中1眼)和0.6%(171眼中1眼)。
  • 布西珠单抗组有1例受试者发生视网膜动脉阻塞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite the effectiveness of existing anti-vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and/or reduce injection or monitoring frequency in patients with diabetic macular edema (DME). OBJECTIVE: To evaluate the efficacy and safety of brolucizumab vs aflibercept dosed every 4 weeks in participants with DME. DESIGN, PARTICIPANTS, AND SETTING: This 52-week, double-masked, phase 3 randomized clinical trial included treatment-naive adults and adults who had previously received anti-VEGF therapy. Data were collected from September 2019 to March 2020, and data were analyzed from April 2020 to February 2021. INTERVENTION: Brolucizumab, 6 mg, intravitreal injection every 4 weeks or aflibercept, 2 mg, intravitreal injection every 4 weeks. MAIN OUTCOMES AND MEASURES: Participants were randomized 2:1 to brolucizumab, 6 mg, or aflibercept, 2 mg. The primary end point was change from baseline in best-corrected visual acuity at week 52. Secondary end points were the proportion of participants with a 2-step improvement or greater from baseline in Diabetic Retinopathy Severity Scale score, the proportion of eyes with absence of both subretinal fluid and intraretinal fluid, change from baseline in central subfield thickness, and safety at week 52. RESULTS: A total of 517 participants were randomized to brolucizumab (n = 346) or aflibercept (n = 171); 299 (57.8%) were male, and the mean (SD) age was 60.7 (10.2) years. Brolucizumab was noninferior to aflibercept in best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study letter score) change from baseline at week 52 (brolucizumab, 12.2-letter improvement; aflibercept, 11.0-letter improvement; difference, 1.1; 95% CI, -0.6 to 2.9; noninferiority margin, 4; P < .001). Brolucizumab was superior to aflibercept for the proportion of eyes without subretinal and intraretinal fluid (brolucizumab, 144 of 346 [41.6%]; aflibercept, 38 of 171 [22.2%]; difference, 20.0%; 95% CI, 12.5to 28.6; P < .001) and mean central subfield thickness change from baseline at week 52 (brolucizumab, -237.8 μm; aflibercept, -196.5 μm; difference, -41.4; 95% CI, -58.9 to -23.8; P < .001). Incidence of intraocular inflammation was 4.0% (14 of 346) in the brolucizumab arm and 2.9% (5 of 171) in the aflibercept arm, incidence of retinal vasculitis was 0.9% (3 of 346) and 0.6% (1 of 171), respectively, and incidence of retinal vascular occlusion was 0.3% (1 of 346) and 0.6% (1 of 171). One participant in the brolucizumab arm had retinal artery occlusion. CONCLUSIONS AND RELEVANCE: In these study participants with DME, no clinically meaningful differences in visual outcomes were noted between the brolucizumab and aflibercept arms; some superior anatomic improvements were noted in the brolucizumab arm. No new safety concerns were identified. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03917472.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Singh RP, Barakat MR, Ip MS, et al. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 37971723. doi:10.1001/jamaophthalmol.2023.5248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。